Rheumatology

Latest News

Older adult holding several pills and glass of water | Image credit: Kotchakorn – stock.adobe.com
Polypharmacy Common in Rheumatoid Arthritis, Driving Risk of Serious Drug Interactions

August 13th 2025

More than 8 in 10 patients with rheumatoid arthritis were taking 5 or more medications at once, a practice linked to older age, multiple comorbidities, and more than 2000 potential drug-to-drug interactions.

Juvenile arthritis awareness month | Image credit: Ocha Designs – stock.adobe.com
Adalimumab, Etanercept Biosimilars Deliver Real-World Results for Juvenile Idiopathic Arthritis

July 29th 2025

Group of doctors talking and looking at tablet | Image credit: Seventyfour – stock.adobe.com
Patients With RA and Cancer Seek More Clarity, Collaboration in Treatment Decisions

July 9th 2025

Older woman eating salad on yoga mat | Image credit: Prostock-studio – stock.adobe.com
Plant-Based Diet May Improve Stress-Related Metrics in Rheumatoid Arthritis

July 3rd 2025

Dentist consulting patient | Image credit: D Theron/peopleimages.com – stock.adobe.com
Dental Infections Pose Risks for Hospitalized Patients With Rheumatoid Arthritis

June 30th 2025

More News

Site Logo
November 14th 2019

Sarilumab as a Combination or Monotherapy Successfully Targets IL-6, Improves Symptoms in Patients With RA

Laura Joszt, MA
Patients with rheumatoid arthritis (RA) not only deal with functional impairment, but also pain, fatigue, and other symptoms driven by interleukin (IL)-6 levels. In a session at the American College of Rheumatology’s annual meeting, 2 speakers examined the role of IL-6 in RA and treatment using sarilumab (Kevzara) to target and block IL-6 signals.
Site Logo
November 13th 2019

Using Technology and Virtual Reality to Improve Outcomes, Quality of Life

Laura Joszt, MA
New technologies that can monitor sleep, track itching patterns, or assist with pain are improving outcomes and quality of life for patients with rheumatologic conditions, according to panelists at the American College of Rheumatology’s annual meeting.
Site Logo
November 13th 2019

Evaluating Sarilumab's Efficacy as a Monotherapy in Rheumatoid Arthritis

Laura Joszt, MA
Monotherapy was a big topic of conversation at the American College of Rheumatology’s annual meeting, held November 8-13 in Atlanta, Georgia, and 2 abstracts highlight the efficacy of sarilumab as a monotherapy in patients with rheumatoid arthritis.
Dr Stephen Messier Discusses the Importance of Nonpharmacologic Interventions in Knee OA
November 13th 2019

Dr Stephen Messier Discusses the Importance of Nonpharmacologic Interventions in Knee OA

Since there are no cures for knee osteoarthritis (OA), exercise and weight loss remain the best first-line therapies to decrease pain and improve function, said Stephen P. Messier, PhD, professor and director of the J.B. Snow Biomechanics Laboratory at Wake Forest University.
Site Logo
November 12th 2019

Sarilumab Reduces Unacceptable Pain, Lowers Glucocorticoid Doses, and Costs Less per Responder Than Comparators

Laura Joszt, MA
Patients with rheumatoid arthritis receiving sarilumab have lower odds of unacceptable pain and are able to reduce their dose of oral glucocorticoid; they also have lower costs per responder than most other treatments, according to a trio of abstracts presented at the American College of Rheumatology/Association of Rheumatology Professionals 2019 Annual Meeting.
Dr Elaine Husni: Huge Savings With Biosimilars Have Not Manifested
November 12th 2019

Dr Elaine Husni: Huge Savings With Biosimilars Have Not Manifested

While biosimilars have brought down the cost of therapies, the savings are not quite as huge as providers may have been led to believe when biosimilars were initially under development, said Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic.
Dr Jeffrey Curtis Discusses Using Live Virus Vaccines in Immunocompromised Patients
November 11th 2019

Dr Jeffrey Curtis Discusses Using Live Virus Vaccines in Immunocompromised Patients

Patients with immunosuppressive conditions, particularly those being treated with tumor necrosis factor inhibitors, are vulnerable to infections, but rheumatologists have mostly been hesitant to use any live virus vaccines in these patients, said Jeffrey R. Curtis, MD, MS, MPH, professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham.
Site Logo
November 11th 2019

Using Patient Characteristics to Predict Clinical Outcomes in RA

Laura Joszt, MA
Grouping patients into clusters based on shared characteristics, such as disease control and general health, may be helpful in understanding and predicting clinical outcomes in patients with rheumatoid arthritis (RA), according to an abstract presented at the 2019 ACR/ARP Annual Meeting, held November 8-13 in Atlanta, Georgia.
Dr Yusuf Yazici Discusses Disease Activity Assessment Tools in RA, Osteoarthritis
November 11th 2019

Dr Yusuf Yazici Discusses Disease Activity Assessment Tools in RA, Osteoarthritis

Disease activity assessments can help physicians treat to targets, but in some areas those targets have not been set yet, said Yusuf Yazici, MD, clinical associate professor in the Department of Medicine at NYU Langone Health.
Site Logo
November 10th 2019

2019 Brought Impressive Results for TNF Inhibitors, Research Into Monotherapy, Interest in CBD

Laura Joszt, MA
This year has been an exciting time for rheumatologists with impressive clinical trial results and promising outcomes for patients, said Susan Manzi, MD, MPH, codirector of the Lupus Center of Excellence and chair of the Department of Medicine of West Penn Allegheny Health System, during a session at the American College of Rheumatology annual meeting in Atlanta, Georgia.
Site Logo
September 24th 2019

Real-World Outcomes Among Patients With Early Rapidly Progressive Rheumatoid Arthritis

Andrew J. Klink, PhD, MPH Tammy G. Curtice, PharmD, MBA, MS Kiran Gupta, PhD, MPharm Kenneth W. Tuell, RPh, BCGP A. Richard Szymialis, RPh Damion Nero, PhD Bruce A. Feinberg, DO
This study suggests that lower healthcare resource use and achieving low disease activity are associated with first-line abatacept compared with a first-line tumor necrosis factor-α inhibitor for patients with early rapidly progressive rheumatoid arthritis.
Treating RA With Anti-TNF Agents Is Linked With a Higher Risk of Incident Psoriasis
August 19th 2019

Treating RA With Anti-TNF Agents Is Linked With a Higher Risk of Incident Psoriasis

Kelly Davio
Biologics have become the standard of care for rheumatoid arthritis (RA) that fails to respond adequately to conventional disease-modifying antirheumatic agents (DMARDs), and overall, these agents are safe and effective. However, an association between treatment with anti–tumor necrosis factor (anti-TNF) agents and new-onset psoriasis in patients with RA has been observed.
Controlling Autoimmune Disease and Impact on Maternal Health
November 26th 2018

Controlling Autoimmune Disease and Impact on Maternal Health

Autoimmune Disease & Maternal Health: Improvements in Treatment
November 26th 2018

Autoimmune Disease & Maternal Health: Improvements in Treatment

Breastfeeding and Autoimmune Disease
November 26th 2018

Breastfeeding and Autoimmune Disease

Autoimmune Disease & Pregnancy: Establishing a Care Plan
November 26th 2018

Autoimmune Disease & Pregnancy: Establishing a Care Plan

Autoimmune Disease, Conception, and Disease Control
November 26th 2018

Autoimmune Disease, Conception, and Disease Control

Family Planning and Autoimmune Disease
November 26th 2018

Family Planning and Autoimmune Disease

Maternal–Fetal Medicine and Autoimmune Disease
November 26th 2018

Maternal–Fetal Medicine and Autoimmune Disease

Implications of Using TNF Inhibitors During Lactation
November 26th 2018

Implications of Using TNF Inhibitors During Lactation

The CRADLE Trial and Autoimmune Disease
November 26th 2018

The CRADLE Trial and Autoimmune Disease

TNF Inhibitors and Pregnancy
November 26th 2018

TNF Inhibitors and Pregnancy

Managing Autoimmune Disease Post Partum
November 26th 2018

Managing Autoimmune Disease Post Partum

Treatment Considerations for Childbearing and Autoimmune Disease
November 26th 2018

Treatment Considerations for Childbearing and Autoimmune Disease

Pregnancy and Autoimmune Disease
November 26th 2018

Pregnancy and Autoimmune Disease

TNF Inhibitors and Autoimmune Disease
November 26th 2018

TNF Inhibitors and Autoimmune Disease

Treatment Considerations and Autoimmune Disease
November 26th 2018

Treatment Considerations and Autoimmune Disease

A Clinical Background on Autoimmune Disease
November 26th 2018

A Clinical Background on Autoimmune Disease

Advances in Inflammation Control Throughout Pregnancy
November 26th 2018

Advances in Inflammation Control Throughout Pregnancy

Counseling Patients on Inflammation Control and Pregnancy
November 26th 2018

Counseling Patients on Inflammation Control and Pregnancy

<1
...
567891011>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo